A practical reference on peptide backbone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
As of August 2018, pembrolizumab is indicated for the treatment of those with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 10] as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. In November 2018, the US FDA granted accelerated approval to pembrolizumab for those with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. In February 2019, the US FDA approved pembrolizumab for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. The FDA granted the application orphan drug designation. In June 2019, the US FDA granted accelerated approval to pembrolizumab for those with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy, and the FDA approved pembrolizumab for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). Pembrolizumab was approved for use in combination with platinum and fluorouracil (FU) for all patients and as a single agent for patients whose tumors express PD‑L1 (Combined Positive Score [CPS] ≥ 1) as determined by an FDA‑approved test.
Acetyl transacylase transfers the acetyl group of acetyl-CoA onto the sulfhydryl group of Acyl Carrier Protein (ACP), releasing CoA and forming acetyl-ACP. An equivalent reaction occurs for malonyl-CoA, in which malonyl transacylase transfers the malonyl group from malonyl-CoA to the sulfhydryl group of Acyl Carrier Protein (ACP), releasing CoA and forming malonyl-ACP. These two reactions are essential, as they prime the acetyl and malonyl groups for condensation in the subsequent chain elongation reaction step. After the production of acetyl-ACP and malonyl-ACP, fatty acid synthesis begins to cycle through repetitions of the following reaction sequence: condensation → reduction → dehydration → reduction. Ultimately, this elongation reaction sequence repeats through 7 cycles to form one molecule of (16C) palmitate, as malonyl-CoA (the carbon donor) adds 2 carbons to the growing chain per cycle. During the third reaction of fatty acid synthesis, acetyl-ACP and malonyl-ACP undergo a condensation reaction catalyzed by the enzyme β-ketoacyl-ACP synthase (also known as acyl-malonyl-ACP condensing enzyme), which produces the four-carbon acetoacetyl-ACP molecule and one molecule of CO2. Notably, the reaction of two-carbon acetyl-ACP with three-carbon malonyl-ACP is more favorable than that of two, two-carbon acetyl-ACP molecules reacting together. The fourth step of fatty acid elongation is the reduction of acetoacyl-ACP to β-hydroxyacyl-ACP, in a reaction catalyzed by 3-ketoacyl-ACP reductase.
=== Genotoxicity === WHO concluded that patulin is genotoxic based on variable genotoxicity data, however it is considered a group 3 carcinogen by the International Agency for Research on Cancer (IARC) since data was inconclusive.
Sources: en.wikipedia.org
Jake Melksham (born 29 August 1991) is a former professional Australian rules footballer who played for Melbourne Football Club and the Essendon Football Club in the Australian Football League (AFL). A midfielder, 1.86 metres (6 ft 1 in) tall and weighing 83 kilograms (183 lb), Melksham also has the ability to play as a defender, primarily as a half-back flanker. Growing up in Glenroy, Victoria, he played top-level football early when he joined the Calder Cannons' under 18 side in the TAC Cup at the age of sixteen. He spent three years playing for the Calder Cannons, winning a premiership in his final junior year. His achievements as a junior include state representation and the TAC Medal as the best player on the ground in the TAC Cup Grand Final. Melksham's late surge in his draft year saw him recruited by the Essendon Football Club with the tenth selection in the 2009 AFL draft. He made his AFL debut in the 2010 season and was rewarded with an AFL Rising Star nomination. He spent six seasons with Essendon, which peaked with a fifth-place finish in the best and fairest, and after 114 games with the club, he was traded to the Melbourne Football Club during the 2015 trade period. Before he could play his first match with Melbourne, he was suspended for the 2016 season for his involvement in the Essendon Football Club supplements saga; he was the last remaining player involved in the saga at the time of his retirement in 2026. In November 2023 he was delisted by the Melbourne Football Club, then re-listed in the subsequent rookie draft.
These drugs are expected to restore a normal libido in patients. Targeting acquired and generalized hypoactive sexual desire disorder (HSDD), improvement in sexual desire, and alleviation of psychological stress are to relieve the correlated symptoms. However, the treatments cannot cope with medically or psychiatrically related conditions, nor the effects from other medications.
=== Azerbaijani === In Azerbaijani, which is an agglutinative language, there is theoretically no limit on word compounding.An example is the 42-letter word Elektrikləşdirdiklərimizdənsinizmişcəsinə; pronounced [elektɾiklæʃdiɾdiklæɾimizˈdænsinizmiʃdʒæsinæ] , which translates to "As if you were from those ones we have electrified". There is a shorter more well-known 32-long word, which is a tongue twister, too — Elektrikləşdirilmişlərdənsinizmi?; pronounced [elektɾiklæʃdiɾilmiʃlæɾˈdænsinizmi] meaning "Are you from the ones who are electrified?".
Sources: en.wikipedia.org
Cysteine proteases, also known as thiol proteases, are hydrolase enzymes that degrade proteins. These proteases share a common catalytic mechanism that involves a nucleophilic cysteine thiol in a catalytic triad or dyad. Discovered by Gopal Chunder Roy in 1873, the first cysteine protease to be isolated and characterized was papain, obtained from Carica papaya. Cysteine proteases are commonly encountered in fruits including the papaya, pineapple, fig, and kiwifruit. The proportion of protease tends to be higher when the fruit is unripe. In fact, the latex of dozens of different plant families are known to contain cysteine proteases. Cysteine proteases are used as an ingredient in meat tenderizers.
A general method for analysis of concentration involves the creation of a calibration curve. This allows for the determination of the amount of a chemical in a material by comparing the results of an unknown sample to those of a series of known standards. If the concentration of an element or compound in a sample exceeds the detection range of the technique, it can simply be diluted in a pure solvent. If the amount in the sample is below an instrument's range of measurement, the method of addition can be used. In this method, a known quantity of the element or compound under study is added, and the difference between the concentration added and the concentration observed is the amount actually in the sample.
In the wake of the rebel capture of Damascus, several places in the capital were ransacked, including Iran's embassy, Assad's estates, and government offices; the Central Bank of Syria was besieged and the reception hall of the Presidential Palace was set on fire. Statues of Hafez al-Assad were toppled nationwide. The Russian and Chinese embassies were untouched. The rebels announced a 13-hour curfew in the capital amidst heavy armed rebel presence and traffic in the capital. Syrian State Television, now under rebel control, resumed broadcasting. Al-Assad clan members expressed resentment over the escape of Bashar and his close family, with one relative stating that "Everyone feels he betrayed them". Israel bombed the Mezzeh Air Base in Damascus. Another strike targeted an alleged Iranian research center used for missile development in the Kafr Sousa district. The Israeli army also crossed the border into Syria, seizing territory adjacent to the border after it was abandoned by the Syrian Army. HTS leader Ahmed al-Sharaa became the de facto leader of Syria on 8 December 2024 as the General Commander and head of the New Syrian Administration, serving until 29 January 2025, when he was appointed President of Syria by the Syrian General Command. Mohammed al-Bashir, head of the Syrian Salvation Government, was appointed prime minister of the Syrian caretaker government on 10 December and served until 29 March 2025.
Congenital afibrinogenemia is a rare and generally autosomal recessive inherited disorder in which blood does not clot due to a lack of fibrinogen (plasma fibrinogen levels typically) but sometimes detected at extremely low levels, e.g. <10 mg/dl. This severe disorder is usually caused by mutations in both the maternal and paternal copies of either the FGA, FGB, or FBG gene. The mutations have virtually complete genetic penetrance with essentially all homozygous bearers experiencing frequent and sometimes life-threatening episodes of bleeding and/or thrombosis. Pathological bleeding occurs early in life, for example often being seen at birth with excessive hemorrhage from the navel.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.